au.\*:("ZANABONI, F")
Results 1 to 19 of 19
Selection :
Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomyBOLIS, G; VILLA, A; GUARNERIO, P et al.Cancer. 1996, Vol 77, Num 1, pp 128-131, issn 0008-543XArticle
Prognostic factors in advanced epithelial ovarian cancerMARSONI, S; TORRI, V; GAMBINO, A et al.British journal of cancer. 1990, Vol 62, Num 3, pp 444-450, issn 0007-0920, 7 p.Article
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric studyZANABONI, F; GRIJUELA, B; DITTO, A et al.European journal of cancer (1990). 2013, Vol 49, Num 5, pp 1065-1072, issn 0959-8049, 8 p.Article
'State of the art' of radical hysterectomy; current practice in European oncology centresTRIMBOS, J. B; FRANCHI, M; ZANABONI, F et al.European journal of cancer (1990). 2004, Vol 40, Num 3, pp 375-378, issn 0959-8049, 4 p.Article
Endometrial thickness in tamoxifen-treated patients : An independent predictor of endometrial diseaseFRANCHI, M; GHEZZI, F; DONADELLO, N et al.Obstetrics and gynecology (New York. 1953). 1999, Vol 93, Num 6, pp 1004-1008, issn 0029-7844Article
High-dose intensity regimens with epirubicin in ovarian cancerVERMORKEN, J. B; BOLIS, G; PINEDO, H. M et al.Seminars in oncology. 1994, Vol 21, Num 1, pp 17-22, issn 0093-7754, SUP1Article
Salvage chemotherapy for ovarian cancer recurrence : weekly cisplatin in combination with epirubicin of etoposideZANABONI, F; SCARFONE, G; PRESTI, M et al.Gynecologic oncology (Print). 1991, Vol 43, Num 1, pp 24-28, issn 0090-8258Article
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupAAPRO, M. S; VAN WIJK, F. H; FRANCHI, M et al.Annals of oncology. 2003, Vol 14, Num 3, pp 441-448, issn 0923-7534, 8 p.Article
Nonclosure of peritoneum at radical abdominal hysterectomy and pelvic node dissection : A randomized studyFRANCHI, M; GHEZZI, F; ZANABONI, F et al.Obstetrics and gynecology (New York. 1953). 1997, Vol 90, Num 4, pp 622-627, issn 0029-7844, 1Article
Adjuvant treatment for early epithelial ovarian cancer : results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)BOLIS, G; COLOMBO, N; ZANABONI, F et al.Annals of oncology. 1995, Vol 6, Num 9, pp 887-893, issn 0923-7534Article
Evaluation of the interaction of mononuclear phagocytes with ovarian carcinoma cells in a colony assayPERI, G; ZANABONI, F; ROSSINI, S et al.British journal of cancer. 1986, Vol 53, Num 1, pp 47-52, issn 0007-0920Article
Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumorsALLAVENA, P; ZANABONI, F; ROSSINI, S et al.Journal of the National Cancer Institute. 1986, Vol 77, Num 4, pp 863-868, issn 0027-8874Article
Natural killer cells in intravenous drug abusers with lymphadenopathy syndromePOLI, G; INTRONA, M; ZANABONI, F et al.Clinical and experimental immunology (Print). 1985, Vol 62, Num 1, pp 128-135, issn 0009-9104Article
Clinical and pharmacological phase I evaluation of Exherin™ (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumoursPEROTTI, A; SESSA, C; ZANABONI, F et al.Annals of oncology. 2009, Vol 20, Num 4, pp 741-745, issn 0923-7534, 5 p.Article
Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancerBOLIS, G; VAN ZAINTEN-PRZYBYSZ, I; SCARFONE, G et al.Gynecologic oncology (Print). 1996, Vol 63, Num 1, pp 62-65, issn 0090-8258Article
Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis : a phase II trial in womenFRANCHI, M; DONADELLO, N; ZANABONI, F et al.Oncology. 1995, Vol 52, Num 6, pp 509-512, issn 0030-2414Article
Tumor antigen CA 125 as a marker of ovarian epithelial carcinomaZANABONI, F; VERGADORO, F; PRESTI, M et al.Gynecologic oncology (Print). 1987, Vol 28, Num 1, pp 61-67, issn 0090-8258Article
Induction of cytotoxicity by interleukin-2 in Tγ-lymphoproliferative disordersALLAVENA, P; INTRONA, M; RAMBALDI, A et al.International journal of cancer. 1986, Vol 37, Num 1, pp 27-33, issn 0020-7136Article
